Who
Justin B. Klee
Co-Chief Executive Officer
Company insider
Files Form 4 as: Co-Chief Executive Officer, Amylyx Pharmaceuticals.
In numbers
- Trades disclosed
- 59
- Buys
- 0
- Sells
- 16
- Bought
- $0
- Sold
- $11.4M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 6 Jan 2022
- Last trade
- 10 Sep 2026
- Last filed
- 14 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Sep 2026filed 14 Sep 2026 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $933K29,025 at $32.13 | filing |
| 10 Sep 2026filed 14 Sep 2026 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $48K1,439 at $33.16 | filing |
| 10 Sep 2026filed 14 Sep 2026 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $933K29,025 at $32.13 | filing |
| 10 Sep 2026filed 14 Sep 2026 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $48K1,439 at $33.16 | filing |
| 18 Aug 2026filed 20 Aug 2026 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —60,039 at $0.00 | filing |
| 18 Aug 2026filed 20 Aug 2026 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —60,039 at $0.00 | filing |
| 5 Mar 2026filed 9 Mar 2026 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —248,865 at $0.00 | filing |
| 5 Mar 2026filed 9 Mar 2026 | AMLX Amylyx Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —373,295 at $0.00 | filing |
| 5 Mar 2026filed 9 Mar 2026 | AMLX Amylyx Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —373,295 at $0.00 | filing |
| 5 Mar 2026filed 9 Mar 2026 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —248,865 at $0.00 | filing |
| 2 Mar 2026filed 4 Mar 2026 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $424K29,282 at $14.47 | filing |
| 2 Mar 2026filed 4 Mar 2026 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $424K29,282 at $14.47 | filing |
| 2 Feb 2026filed 4 Feb 2026 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $228K15,500 at $14.69 | filing |
| 2 Feb 2026filed 4 Feb 2026 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $228K15,500 at $14.69 | filing |
| 16 Jan 2026filed 20 Jan 2026 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $22K2,847 at $7.57 | filing |
| 16 Jan 2026filed 20 Jan 2026 | AMLX Amylyx Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,847 at $0.00 | filing |
| 16 Jan 2026filed 20 Jan 2026 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $28K1,995 at $13.89 | filing |
| 16 Jan 2026filed 20 Jan 2026 | AMLX Amylyx Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,847 at $0.00 | filing |
| 16 Jan 2026filed 20 Jan 2026 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $22K2,847 at $7.57 | filing |
| 16 Jan 2026filed 20 Jan 2026 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $28K1,995 at $13.89 | filing |
News
Amylyx Pharmaceuticals (NASDAQ:AMLX) Price Target Raised to $39.00AMLX · dailypolitical.com · 18 Oct 2026
0 headlines in the last 90 days name Justin B. Klee; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.